Market Research Report
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 8th Edition
|Published by||Kalorama Information||Product code||302663|
|Published||Content info||342 Pages
Delivery time: 1-2 business days
|Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 8th Edition|
|Published: March 20, 2018||Content info: 342 Pages||
What's happening in the drug discovery market? How much are pharma companies outsourcing? What parts of the process are seeing volume by CROS? What's happening in China and Eastern Europe? Which companies are in leadership in the market?
In eight editions, Kalorama Information's report, Outsourcing in Drug Discovery, has provided answers to these questions and more. As the pharmaceutical industry seeks to boost production recover from a lack of blockbusters, and patients and providers demand effective biotherapies, the race to discover new drugs is more. Kalorama provides information unavailable from any other source, the result of interviews with companies and experts, as well as economic research from Kalorama's proprietary database.
This report, Outsourcing in Drug Discovery, 8th Edition, contains 2017 market size estimates and 2022 forecasts for 21 different parts of the process that might be outsourced, including:
For each of these categories, market size is provided and forecasts are given to 2022. The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, a molecule that affects biological function by binding to a target protein or nucleic acid in a way that is useful for treatment of disease. The process by which molecules are identified for their therapeutic value involves synthesis and analysis of many derivatives of the original leads. There are several steps in the drug discovery process including hit confirmation, lead generation, lead optimization, and other studies. Drug discovery is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will actually yield products that achieve regulatory approval by the Food & Drug Administration (FDA).
Since the last edition of Kalorama's report on the outsourcing of discovery of novel compounds in the pharmaceutical industry, the industry has seen dramatic change. Pharmaceutical companies facing cutbacks in R&D budgets and new demands for novel products need to outsource aspects of their operations. Core functions once kept in-house such as the discovery of potential new drugs are now commonly outsourced.
Kalorama Information's Outsourcing in Drug Discovery captures this trend, offering unparalleled coverage of the drug discovery outsourcing market. It presents viewpoints from both customers and suppliers. Segments, size, and growth of the market are presented. The trend toward the increased use of offshore suppliers in China, India, Russia and Eastern Europe is covered in detail. The report also provides profiles of 23 suppliers, representative of those active in this market.
Featuring market data and forecasts, the report covers issues such as:
This report provides an in depth look into the trends that have shaped the drug discovery outsourcing market today, and details the current and future global market. The report also profiles companies in the market, including the following: